Sitagliptin could activate NK and T cell chemotaxis through preservation of the CXCR3-CXCL10 axis and suppress tumor angiogenesis in hepatocellular carcinoma, thereby inhibiting tumor growth and improving the immunotherapy effect [47]. The gene discussed is CXCR3; the disease is neoplasm.